549 692
Table 2 – Overview of selected publications addressing specifically patient characteristics, treatment, and outcomes of secondary urethral recurrence
Study
(author, yr)
Total sample
size/
N
(pat)
with SUT (%)
Type of
diversion
OBS/non-OBS;
(% of pat.
with OBS
Sex
(m/w) for
patients
with SUT
Median
(or range)
time to
recurrence
(mo)
Recurrence
pattern
Incidence of
urothelial
recurrence with
OBS vs non-OBS
Treatment for SUT
Outcome
after
treatment
of SUT
Median (mean)
follow-up
(or range)
for total
cohort (mo)
Balci, 2015
[15]287/11 (3.8)
141/146 (49.1)
11/0
n.r.
n.r.
2/9
TUR+BCG:
[16_TD$DIFF]
1; CTx: 4; Ux:
[14_TD$DIFF]
2; RTx: 4 n.r.
29
Boorjian, 2011
[10]1506/85 (5.6)
242/124 (19.5)
78/7
13.3
n.r.
5/80
[57_TD$DIFF]
UX:
[58_TD$DIFF]
73; CTx/RTx:
[44_TD$DIFF]
6; No therapy: 6 DOD:
[59_TD$DIFF]
35; DOC:
[60_TD$DIFF]
38; n.r.: 12
155
Cho, 2009
[14]
412/13 (3.2)
n.r.
n.r.
17
n.r.
n.r.
S only: 5; S+CTx: 6; S+RTx: 1;
CTx only: 1
Alive:
[44_TD$DIFF]
6; Dead: 7
54 (6–227)
Clark, 2004
[49]
1054/47 (4.5)
n.r.
n.r.
18.5 (2–116)
n.r.
14/33
Partial or total Ux:
[61_TD$DIFF]
41;
CTx:
[14_TD$DIFF]
2; CTx+RTx:
[16_TD$DIFF]
1;
Topical 5-FU +/- ENDO: 3
Alive:
[27_TD$DIFF]
10; DOD:
[62_TD$DIFF]
25; DOC: 11
121
Djaladat, 2013
[16]33/2 (6.1)
33/0 (100)
2/0
14/44
U: 2
2/0
n.r.
n.r.
58
Gakis, 2015
[31]
297/7 (2.4)
297/0 (100)
0/7
30
U: 7
7/0
n.r.
n.r.
64
Gaya, 2014
[40]
234/3 (1.3)
68/166 (29.1)
n.r.
26
U: 3
n.r.
S: 3
n.r.
31
Hrbacek
[6_TD$DIFF]
,
[63_TD$DIFF]
2015
[64_TD$DIFF]
[63]
456/12 (2.6)
456/0 (100)
0/12
8
U: 3; U+D:4,
U+P+D: 2; U+P: 3
12/0
S alone: 5; RTx: 2; CTx: 3; BCG: 2 Dead: 9; Alive: 3
64
Huguet, 2008
[11]729/34 (4.7)
219/510 (30.0)
34/0
14
n.r.
5/29
TUR:
[14_TD$DIFF]
2; BCG:
[16_TD$DIFF]
1; Ux: 31
DOD:
[53_TD$DIFF]
16; DOC:
[55_TD$DIFF]
3;
NED: 15
38
Ichihara
[6_TD$DIFF]
,
[65_TD$DIFF]
2013
[66_TD$DIFF]
[64]
101/2 (2.0)
29/72 (26.1)
2/0
7/24
U: 2
0/2
S: 2
DOD: 2
44
Jentzmik
[6_TD$DIFF]
,
[42_TD$DIFF]
2012
[67_TD$DIFF]
[65]
121/1 (0.8)
121/0 (100)
1/0
n.r.
n.r.
1/0
n.r.
n.r.
56
Kassouf, 2008
[41]252/2 (0.8)
252/0 (100)
2/0
n.r.
n.r.
2/0
n.r.
n.r.
48
Lebret, 1998
[32]
118/0
n.a.
0
n.a.
n.a.
n.a.
n.a.
n.a.
n.a.
Osman, 2012
[34]100/4 (4.0)
n.r.
n.r.
n.r.
U+D: 3, U+P: 1
n.r.
n.r
n.r.
n.r.
Stein, 2005
[17]768/45 (5.9)
397/371 (51.7)
n.a.
24
n.a.
n.a.
n.a.
n.a.
156
Taylor
[6_TD$DIFF]
,
[68_TD$DIFF]
2010
[69_TD$DIFF]
[66]
260/6 (2.3)
260/0 (100)
n.r.
29
U: 6
6/0
CTx: 1; Ux:
[14_TD$DIFF]
2; UKN:
[16_TD$DIFF]
1; CTx+Ux:
[16_TD$DIFF]
1; TUR: 1
AWD:
[16_TD$DIFF]
1; NED:
[29_TD$DIFF]
4; DOD: 1
61
Varol, 2004 [47]
371/15 (4.0)
371/0 (100)
15/0
14 (3–70)
U: 11; U+D: 4
15/0
BCG:
[21_TD$DIFF]
8; BCG+Ux:
[55_TD$DIFF]
3; CTx:
[14_TD$DIFF]
2; No local therapy: 2
DOD:
[
26_TD$DIFF]
7; DOC:
[55_TD$DIFF]
3; Alive: 5
n.r.
AWD = alive with disease; BCG = Bacille-Calmette Guerin; CTx = systemic chemotherapy; D = distant recurrence; DOC = death of other cause; DOD = death of disease; ENDO = endoscopic management; 5-FU = 5-
fluorouracil; m = men;
N
= number; n.a. = not applicable; non-OBS = non orthotopic bladder substitute; n.r. = not reported; NED = no evidence of disease; OBS = orthotopic bladder substitute; P = pelvic recurrence;
pat. = patients; RTx = radiotherapy; S = surgery; SUT = secondary urethral tumor; TUR = transurethral resection; w = women; w/o = without; U = urothelial recurrence; UKN = unknown; Ux = urethrectomy.
E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 5 4 5 – 5 5 7
549